drugset / Trial / NCT04542434

Niclosamide in COVID-19

NCT04542434

Phase 2 Withdrawn Entero Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a two-part, Phase 2, multicentre, randomized, double blind, 2-arm placebo-controlled study in adults with moderate COVID-19 with gastrointestinal signs and symptoms

Timeline

Start
2022-01-20
Primary completion
2022-01-20
Completion
2022-01-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Niclosamide Unknown 400 mg Oral

Indications